Literature DB >> 11118385

Adjunctive salvage therapy with inhaled aminoglycosides for patients with persistent smear-positive pulmonary tuberculosis.

L V Sacks1, S Pendle, D Orlovic, M Andre, M Popara, G Moore, L Thonell, S Hurwitz.   

Abstract

A proportion of patients with drug-resistant and drug-susceptible tuberculosis (TB) have sputum that is smear and culture positive for Mycobacterium tuberculosis for a prolonged period of time, despite conventional therapy. Among such patients with refractory TB, an unblinded, observational study was undertaken that used conventional TB therapy and adjunctive aerosol aminoglycosides. Patients with persistent smear- and culture-positive sputum for M. tuberculosis (despite > or =2 months of optimal systemic therapy) were selected for adjunctive treatment via inhalation with aminoglycosides, and microbiological responses were monitored. Thirteen of 19 patients converted to smear negativity during the study: 6 of 7 with drug-susceptible TB and 7 of 12 with drug-resistant TB. Among patients with drug-susceptible TB, the median time to sputum conversion was 23 days, a shorter time than for a population of historical control patients. Recurrent infection was not observed. Adjunctive aerosol aminoglycosides may expedite sterilization of sputum among certain patients with refractory TB and diminish the risk of transmission.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11118385     DOI: 10.1086/317524

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  10 in total

1.  Aerosolized gentamicin reduces the burden of tuberculosis in a murine model.

Authors:  Chad J Roy; Satheesh K Sivasubramani; Noton K Dutta; Smriti Mehra; Nadia A Golden; Stephanie Killeen; James D Talton; Badre E Hammoud; Peter J Didier; Deepak Kaushal
Journal:  Antimicrob Agents Chemother       Date:  2011-12-05       Impact factor: 5.191

2.  Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation.

Authors:  Jean C Sung; Lucila Garcia-Contreras; Jarod L Verberkmoes; Charles A Peloquin; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2009-01-12       Impact factor: 5.191

Review 3.  Inhaled drug delivery for tuberculosis therapy.

Authors:  Pavan Muttil; Chenchen Wang; Anthony J Hickey
Journal:  Pharm Res       Date:  2009-11       Impact factor: 4.200

Review 4.  Inhalation of sustained release microparticles for the targeted treatment of respiratory diseases.

Authors:  Gauthami Pulivendala; Swarna Bale; Chandraiah Godugu
Journal:  Drug Deliv Transl Res       Date:  2020-04       Impact factor: 4.617

5.  Polymeric Microparticles: Synthesis, Characterization and In Vitro Evaluation for Pulmonary Delivery of Rifampicin.

Authors:  Faiqa Falak Naz; Kifayat Ullah Shah; Zahid Rasul Niazi; Mansoor Zaman; Vuanghao Lim; Mulham Alfatama
Journal:  Polymers (Basel)       Date:  2022-06-19       Impact factor: 4.967

6.  Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs.

Authors:  Lucila Garcia-Contreras; Jean C Sung; Pavan Muttil; Danielle Padilla; Martin Telko; Jarod L Verberkmoes; Katharina J Elbert; Anthony J Hickey; David A Edwards
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

7.  Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin.

Authors:  Jennifer Fiegel; Lucila Garcia-Contreras; Matthew Thomas; Jarod VerBerkmoes; Katharina Elbert; Anthony Hickey; David Edwards
Journal:  Pharm Res       Date:  2007-07-27       Impact factor: 4.200

Review 8.  Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs.

Authors:  Miriam Braunstein; Anthony J Hickey; Sean Ekins
Journal:  Pharm Res       Date:  2019-10-24       Impact factor: 4.200

9.  Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series.

Authors:  Kala K Davis; Peter N Kao; Susan S Jacobs; Stephen J Ruoss
Journal:  BMC Pulm Med       Date:  2007-02-23       Impact factor: 3.317

10.  Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies.

Authors:  Mohammad A M Momin; Bhamini Rangnekar; Shubhra Sinha; Chen-Yi Cheung; Gregory M Cook; Shyamal C Das
Journal:  Pharmaceutics       Date:  2019-10-01       Impact factor: 6.321

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.